Preparation method and application of medicinal and edible compound extract for improving myelosuppression after tumor chemotherapy

Abstract

The invention relates to a medicinal and edible compound extract for improving myelosuppression of a tumor patient after chemotherapy, and a preparation method and application of the medicinal and edible compound extract. The compound extract is extracted from a composition at least comprising the following raw material medicines in parts by weight: 0.9-10 parts of tricholoma matsutake, 0.9-10 parts of mulberry and 0.5-10 parts of rhizoma polygonati. The raw material medicine composition further comprises the following raw material medicines in parts by weight: 0.7-10 parts of longan, 0.5-10 parts of pericarpium citri reticulatae, 0.5-10 parts of scorched hawthorn fruit, 0.5-10 parts of fructus amomi, 1.1-10 parts of cordyceps sinensis rice flour and 2.5-15 parts of rice peptide. The selected raw material medicines are all medicinal and edible components, do not cause adverse effects on liver and kidney functions and gastrointestinal tracts of eaters, and are high in safety and high in patient acceptance degree. Effect verification results show that the mulberry compound extract has an improvement effect on the side effect of bone marrow suppression of tumor patients, especially in the early stage, no related adverse reaction is found, and a safe and effective treatment choice is provided for bone marrow suppression.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine compositions, specifically to a compound extract for improving the myelosuppression side effects of radiotherapy and chemotherapy in cancer patients, its preparation method, and its application in the preparation of drug formulations for improving the myelosuppression side effects of radiotherapy and chemotherapy in cancer patients. Background Technology

[0002] The incidence of cancer continues to rise, making it one of the leading diseases threatening human health. Radiotherapy and chemotherapy are important treatments for cancer, but while they play a positive role, they also damage normal cells, especially causing severe damage to the hematopoietic system, such as bone marrow suppression. Bone marrow suppression, a major side effect of radiotherapy or chemotherapy, manifests primarily as a decrease in white blood cell and platelet counts, leading to anemia, bleeding, immunosuppression, and even fatal infections. This interrupts the cancer treatment process, severely impacting the patient's quality of life and prognosis, not only delaying treatment progress and affecting its effectiveness but also endangering the patient's life, becoming a leading cause of death. Therefore, the treatment of bone marrow suppression is receiving increasing attention, and its rational and effective treatment is a crucial aspect of cancer treatment.

[0003] Clinical treatments for bone marrow suppression include traditional white blood cell boosting drugs, such as Leucogen, Shark Liver Extract, and Shengbai'an Tablets, which have slow effects and limited efficacy. Injectable drugs, such as leucogen and recombinant human granulocyte colony-stimulating factor, act rapidly but have drawbacks such as short duration of action and easy regression. Component blood transfusions, bone marrow transplantation, and peripheral hematopoietic stem cell transplantation are effective but expensive. In fact, patients with malignant tumors and their families tend to choose safer, more effective, and longer-lasting treatment options. Currently, nutritional support primarily uses complete nutritional preparations, special complete nutritional preparations, and incomplete nutritional component preparations as nutritional substrates, but no effect on improving bone marrow suppression has been observed.

[0004] The use of medicinal and edible plants in my country has a long history and has played a significant role in the health and well-being of the Chinese people. In recent years, an increasing number of scientific studies have highlighted the health benefits of bioactive substances derived from these medicinal and edible plants. According to the list of 101 items that are both medicinal and edible issued by the former National Health and Family Planning Commission, these items fall between health products and medicines, and their bioactive substances are considered to possess both the therapeutic effects of medicines and the safety and stability of food. However, research reveals that current studies on alleviating myelosuppression are mostly focused on the pharmaceutical field. For example, Chinese invention patent CN105343198A discloses a pharmaceutical composition for preventing and treating myelosuppression, prepared from 29-46 parts by weight of *Gynostemma pentaphyllum* and 30-60 parts by weight of *Broussonetia papyrifera*. Chinese invention patent CN110025674A discloses a traditional Chinese medicine composition for treating myelosuppression during chemotherapy, prepared from the following proportions of traditional Chinese medicinal materials: 6-150 parts of raw *Astragalus membranaceus*, 2-50 parts of *Angelica sinensis*, 2-50 parts of *Eclipta prostrata*, 2-50 parts of *Ligustrum lucidum*, and 2-50 parts of *Psoralea corylifolia*. The Chinese invention patent with patent number CN114306564A discloses a traditional Chinese medicine composition for treating bone marrow suppression after radiotherapy and chemotherapy, consisting of 10-30 parts of Codonopsis pilosula, 30-60 parts of Astragalus membranaceus, 10-30 parts of stir-fried Atractylodes macrocephala, 10-20 parts of Cimicifuga foetida, 10-20 parts of Bupleurum chinense, 10-20 parts of Citrus reticulata peel, 10-20 parts of Angelica sinensis, 10-20 parts of fresh ginger, 10-30 parts of jujube, 10-20 parts of donkey-hide gelatin, 20-40 parts of Eucommia ulmoides, 20-40 parts of Rehmannia glutinosa, 10-30 parts of Ligustrum lucidum, 10-20 parts of deer antler powder, and 10-20 parts of prepared licorice root. Summary of the Invention

[0005] Based on the above research, the present invention aims to provide a compound extract of mulberry and velvet that has both therapeutic and food safety properties, and can alleviate the bone marrow suppression side effects caused by anti-cancer treatment in cancer patients without affecting clinical treatment.

[0006] The "Mulberry and Mulberry Compound Extract" provided by this invention is a bioactive functional nutritional food made primarily from matsutake mushrooms rich in matsutake polysaccharides, supplemented by medicinal and edible plants such as mulberry and polygonatum. According to the Chinese Pharmacopoeia and traditional Chinese medicine literature, matsutake mushrooms have the effects of tonifying essence, nourishing the kidneys, and strengthening yang, while polygonatum tonifies qi, nourishes yin, strengthens the spleen, moistens the lungs, and benefits the kidneys. Furthermore, extensive literature searches have shown that matsutake polysaccharides, polygonatum polysaccharides, and resveratrol, abundant in mulberries, have certain inhibitory effects on tumor cells and enhance immunity. Therefore, the mulberry and mulberry compound extract provided by this invention has a certain ameliorative effect on bone marrow suppression in cancer patients undergoing radiotherapy and chemotherapy, providing a new option for nutritional support for patients with bone marrow suppression.

[0007] In a first aspect, the present invention provides a compound extract of mulberry and mulberry, which is extracted from a combination of raw materials comprising at least the following parts by weight: 0.9 to 10 parts by weight of matsutake mushroom, 0.9 to 10 parts by weight of mulberry, and 0.5 to 10 parts by weight of polygonatum.

[0008] Preferably, the combination of raw materials also includes the following raw materials in parts by weight: 0.7-10 parts longan, 0.5-10 parts dried tangerine peel, 0.5-10 parts roasted hawthorn, 0.5-10 parts amomum villosum, 1.1-10 parts cordyceps rice flour, and 2.5-15 parts rice peptide.

[0009] Furthermore, the preferred combination of raw materials in this invention comprises the following raw materials in parts by weight: 5-5.5 parts matsutake mushroom, 5-5.5 parts mulberry, 5-5.5 parts polygonatum, 5-5.5 parts longan, 5-5.5 parts dried tangerine peel, 5-5.5 parts roasted hawthorn, 5-5.5 parts amomum villosum, 5-6 parts cordyceps rice flour, and 6-8 parts rice peptide.

[0010] In a second aspect, the present invention provides a method for preparing the above-mentioned mulberry and velvet compound extract, comprising the following steps: mixing the above-mentioned raw materials in parts by weight, soaking them in a container for a certain period of time, decocting them under normal pressure, filtering out the liquid, and obtaining an aqueous extract for drinking.

[0011] In practice, add the above-mentioned raw materials to water at a weight-volume ratio of g / 100mL, and then steep or decoct before drinking.

[0012] The formula for a single-person daily dose of the mulberry and matsutake extract is as follows: Mulberry, 0.9–10 g / 100 ml; Matsutake, 0.9–10 g / 100 ml; Longan, 0.7–10 g / 100 ml; Tangerine peel, 0.5–10 g / 100 ml; Roasted hawthorn, 0.5–10 g / 100 ml; Polygonatum, 0.5–10 g / 100 ml; Amomum villosum, 0.5–10 g / 100 ml; Cordyceps rice powder 1.1–10 g / 100 ml; Rice peptide, 2.5–15 g / 100 ml.

[0013] Matsutake mushrooms are a type of fungus used both as food and medicine. They are believed to have benefits for the kidneys, essence, and virility, and also possess anti-tumor properties. Studies have shown that matsutake mushrooms have excellent white blood cell-boosting properties, reducing the decrease in peripheral blood leukocyte count caused by radiotherapy, increasing bone marrow DNA content, and providing some protection against hematopoietic system damage after radiotherapy in tumor-bearing mice. They can also improve the clinical manifestations of cancer patients, promote normal hematopoietic function, and enhance the body's immune function. Furthermore, they can promote bone marrow hematopoiesis in patients with acute non-lymphocytic leukemia, improve bone marrow suppression after chemotherapy, and significantly increase peripheral blood hemoglobin concentration, platelet count, and total white blood cell count compared to the control group.

[0014] Polygonatum, belonging to the Liliaceae family, is used to replenish qi and yin, strengthen the spleen, moisten the lungs, and benefit the kidneys, and also has anti-tumor effects. The *Compendium of Materia Medica* records that Polygonatum "replenishes all deficiencies and fills the essence"; the *Classic of Immortal Herbs and Ganoderma* records that Polygonatum "soothes the middle and benefits qi, harmonizes the five internal organs, makes muscles full, and strengthens bone marrow." Polygonatum polysaccharides are an important active ingredient of Polygonatum. Polygonatum polysaccharides can significantly increase the total number of white blood cells and platelets in the peripheral blood of irradiated mice, and can counteract radiation-induced hematopoietic dysfunction and red blood cell damage. Polygonatum can improve bone marrow hematopoietic function in cyclophosphamide-treated mice, increasing the number of white blood cells and red blood cells. In clinical studies, chemotherapy patients were randomly divided into a traditional Chinese medicine group containing Polygonatum and a control group treated with Western medicine, white blood cell transfusion, blood transfusion, and hormone therapy. After intervention, the white blood cell count in both groups significantly increased, and the effect of increasing white blood cell count was more prolonged in the traditional Chinese medicine group, while some cases in the Western medicine group showed a "regression" in white blood cell count. This indicates that Polygonatum has a good effect on increasing white blood cell count.

[0015] Meanwhile, matsutake polysaccharides, polygonatum polysaccharides, and mulberries are all rich in resveratrol. Resveratrol is a non-flavonoid polyphenol compound with various biological activities and pharmacological effects, including anti-inflammatory and anti-tumor properties, and has significant medicinal value. Resveratrol can promote the differentiation of hematopoietic stem cells, increase the capacity of bone marrow hematopoietic stem cells and progenitor cells, and accelerate their differentiation into terminal blood cells, thereby increasing the number of white blood cells. It can also promote and accelerate the proliferation and recovery of residual hematopoietic stem cells and promote the repair of radiation-induced hematopoietic system damage. Resveratrol can also significantly increase the number of platelets, red blood cells, and white blood cells, and increase the hematopoietic area and the number of nucleated cells.

[0016] In a third aspect, the present invention provides the use of the above-mentioned mulberry and velvet compound extract in the preparation of drugs or health foods that alleviate bone marrow suppression in cancer patients undergoing radiotherapy and chemotherapy.

[0017] The role and effect of invention

[0018] In terms of safety, the Matsutake Mushroom Compound Extract provided by this invention uses matsutake mushroom, which is rich in matsutake polysaccharides, as the main raw material, and is supplemented by mulberry, polygonatum, longan, tangerine peel, hawthorn, cardamom, cordyceps rice powder, and rice peptides, all of which are medicinal and edible plants. The selected raw materials are all medicinal and edible components, which will not have an adverse effect on the liver and kidney function or gastrointestinal tract of consumers. It has high safety and is highly acceptable to patients.

[0019] Regarding efficacy, a 21-day follow-up study was conducted on both the non-mulberry and mulberry groups. White blood cell, granulocyte, hemoglobin, and platelet counts, as well as the occurrence of adverse events, were compared before and after the observation period to evaluate safety and efficacy. Results showed that the mulberry group exhibited significantly higher white blood cell, granulocyte, and platelet counts after 21 days (P<0.05), significantly superior to the non-mulberry group. These results indicate that the mulberry and mulberry compound extract has an ameliorative effect on the side effects of bone marrow suppression in cancer patients, especially in the early stages, and no related adverse reactions were found, providing a safe and effective treatment option for bone marrow suppression. Attached Figure Description

[0020] Figure 1 This is a flowchart of the patient grouping and analysis process of the present invention.

[0021] Figure 2 This invention compares the gender distribution of patients in the non-mulberry and mulberry groups with that in the mulberry and mulberry groups.

[0022] Figure 3 This invention compares the tumor status of patients in the non-mulberry and mulberry groups with those in the mulberry and mulberry groups.

[0023] Figure 4 This invention compares the tumor radiotherapy and chemotherapy outcomes of patients in the non-mulberry and mulberry groups with those in the mulberry and mulberry groups.

[0024] Figure 5 The study compared the changes in blood parameters between the non-mulberry and mulberry groups after 21 days. Among them, (A) is the comparison of changes in hemoglobin, (B) is the comparison of changes in white blood cells, (C) is the comparison of changes in granulocyte count, and (D) is the comparison of changes in platelet count. Detailed Implementation

[0025] The present invention will now be described in detail with reference to the embodiments, but the implementation of the present invention is not limited thereto.

[0026] Unless otherwise specified, the experimental methods used in the following examples were performed under standard conditions or as recommended by the manufacturer. Unless otherwise noted, all medicinal materials used in the embodiments of this invention can be obtained from Chinese herbal medicine sales companies.

[0027] Example 1: Formula of Mulberry and Mushroom Compound Extract

[0028] Mulberry, 0.9–10 g / 100 ml; Matsutake mushroom, 0.9–10 g / 100 ml; Longan, 0.7–10 g / 100 ml; Dried tangerine peel, 0.5–10 g / 100 ml; Roasted hawthorn, 0.5–10 g / 100 ml; Polygonatum sibiricum, 0.5–10 g / 100 ml; Amomum villosum, 0.5–10 g / 100 ml; Cordyceps militaris rice flour, 1.1–10 g / 100 ml; Rice peptide, 2.5–15 g / 100 ml.

[0029] Mix the above-mentioned raw materials into a single small package. Before each use, soak the mixture in 100mL of boiling water and drink it, or boil it in 100mL of cold water under normal pressure, filter out about 80mL of the liquid, and drink the water extract.

[0030] Example 2: Clinical observation effect

[0031] 1. Inclusion criteria

[0032] All participants met the following inclusion criteria: (1) aged 18-75 years, regardless of gender; (2) cancer patients with white blood cell and / or platelet counts below the normal range; (3) able to understand the purpose of the study, willing to participate and sign the informed consent form.

[0033] 2. Exclusion criteria

[0034] Patients with any of the following conditions are ineligible for inclusion: (1) those who are allergic to the ingredients in the study nutritional preparation or have severe gastrointestinal reactions; (2) those with severe systemic diseases and unstable conditions; (3) those with mental illness, including severe hysteria, who lack autonomy; (4) those with liver dysfunction: ALT or AST greater than 3 times the upper limit of normal; (5) those with abnormal renal function: serum creatinine (Cr) greater than 1.5 times the upper limit of normal; (6) those who are pregnant or lactating, or those who plan to become pregnant; (7) those with a history of drug abuse or alcoholism; (8) those who participated in other drug clinical trials within 30 days prior to this study.

[0035] 3. Research Subjects

[0036] This prospective cohort study employed a clinical research methodology to observe patients with gastrointestinal tumors who underwent radiotherapy and chemotherapy at Shanghai Changhai Hospital, 301 Hospital, and Guangzhou Cancer Hospital between September 2018 and September 2019. A total of 255 patients met the inclusion criteria, of whom 9 declined to participate. 246 patients signed informed consent and were divided into a non-mulberry / anthraquinone compound extract group (Group A, n=185) and a mulberry / anthraquinone group (Group B, n=61) based on whether they took the extract. Three patients dropped out of Group A and one dropped out of Group B, leaving 180 patients from Group A and 60 from Group B participating in the data analysis. The detailed research process is as follows: Figure 1 As shown.

[0037] 4. Research Methods

[0038] Within one radiotherapy and chemotherapy cycle, this study observed the effects of using and not using mulberry and deer antler compound extract on bone marrow suppression in two groups of patients with the same disease background and who experienced bone marrow suppression during radiotherapy and chemotherapy. The two groups were matched and followed up according to height, age, BMI, radiotherapy and chemotherapy status, and medication use. Treatment began 7 days (±3 days) before the start of the next chemotherapy cycle, with weekly follow-ups for 21 days. After 21 days, the mean counts of white blood cells, granulocytes, hemoglobin, and platelets were statistically analyzed and compared between the two groups, as well as the mean counts of white blood cells, granulocytes, hemoglobin, and platelets before and after observation in the mulberry and deer antler group, to assess whether the mulberry and deer antler compound extract could effectively improve the bone marrow suppression side effects of radiotherapy and chemotherapy.

[0039] (1) Research Groups:

[0040] Non-mulberry and mushroom group (Group A): Original clinical treatment plan + nutritional education

[0041] Group B (Mulberry and Mushroom Group): Oral administration of mulberry and mushroom compound extract + original clinical treatment plan + nutritional education

[0042] (2) Follow-up period: 21 days, during which the original diet pattern was not changed.

[0043] (3) Dosage and usage: Drink directly, once a day, 80ml each time.

[0044] (4) Combined medication:

[0045] During the follow-up period, the original radiotherapy and chemotherapy regimen for the tumor and the use of drugs to increase white blood cell count will not be affected. All concomitant medications used during the follow-up period must be recorded, including drug name, chemical composition, indication, frequency of use, and adverse reactions.

[0046] 5. Observation Indicators

[0047] (1) The main results include changes in white blood cell, granulocyte, hemoglobin, and platelet counts obtained from routine blood analysis, as well as bone marrow suppression rate.

[0048] (2) Secondary outcomes are as follows: ① Compliance; ② Safety indicators: Adverse events should be recorded weekly, including severity and frequency. Data collected should include any adverse effects, such as liver and kidney function, gastrointestinal reactions, and general condition (vital signs, diet, bowel movements, sleep, skin and mucous membranes, mental state, etc.). Treatment and outcomes of adverse events should also be recorded.

[0049] (3) Grading assessment of bone marrow suppression: Grading is carried out in accordance with the WHO grading criteria for adverse reactions to antitumor drugs. See Table 1 for details.

[0050] Table 1. WHO Grading Criteria for Adverse Reactions of Antitumor Drugs (Hematology Part)

[0051]

[0052] 6. Statistical Analysis

[0053] Statistical analysis was performed using SPSS 23, a professional statistical software. Descriptive statistics and statistical comparisons were conducted on various baseline data before and after the analysis. Normally distributed measurement data were expressed as mean ± standard deviation. The data indicates that paired t-tests were used for within-group comparisons, independent t-tests were used for between-group comparisons with consistent baselines, and multiple linear regression was used to identify relevant factors before analysis of covariance for inconsistent baselines. For non-normally distributed continuous data, data are presented as median, lower 25th percentile, and upper 75th percentile; Wilcoxon tests were used for between-group comparisons. Categorical data are presented as percentages (%); chi-square tests were used for comparisons. Hypothesis testing consistently used two-tailed tests, providing the test statistic and its corresponding p-value. A p-value ≤ 0.05 was considered statistically significant.

[0054] 7. Results Analysis

[0055] (1) Basic information of the two groups of patients

[0056] 240 patients with gastrointestinal tumors undergoing radiotherapy and chemotherapy were divided into two groups based on whether they received mulberry and antler compound extract. Group B consisted of 60 patients, including 31 males (51.7%) and 29 females (48.3%); diseases included: colorectal cancer (34 cases, 56.7%), gastric cancer (15 cases, 25%), and other (11 cases, 18.3%); radiotherapy was received in 4 cases (6.7%), and chemotherapy in 56 cases (93.3%). Group A consisted of 180 patients, including 91 males (50.4%) and 89 females (49.6%); diseases included: colorectal cancer (93 cases, 51.7%), gastric cancer (51 cases, 28.3%), and other (36 cases, 20.0%); radiotherapy was received in 16 cases (8.9%), and chemotherapy in 164 cases (91.1%). There were no statistically significant differences between the two groups in terms of gender, age, height, weight, BMI, and disease background (P>0.05). See details... Figure 2-4 Table 2.

[0057] Table 2 Comparison of basic information between the two groups ( ).

[0058]

[0059] (2) Changes in indicators before and after the two groups of observations

[0060] See results Figure 5 In group B, white blood cell, granulocyte, and platelet counts significantly increased after 21 days (P<0.05). Figure 5 B~5D), hemoglobin showed no significant improvement (P>0.05) Figure 5Group A), and except for hemoglobin, the improvement in other indicators in Group B was significantly better than that in Group A (P<0.05). In the figure, *comparison before and after observation in the mulberry and mushroom group, P<0.05; #comparison of improvement between the two groups after observation, P<0.05.

[0061] (3) Changes in indicators before and after observation in the two groups of patients with grade I and grade II myelosuppression.

[0062] After 21 days, the hemoglobin, white blood cell, granulocyte, and platelet counts in the mulberry and velvet group were significantly increased (P<0.05). After adjusting for factors such as age, height, weight, hemoglobin, white blood cell, granulocyte, and platelet counts before observation, the improvement in each indicator in the mulberry and velvet group was significantly better than that in the non-mulberry and velvet group (P<0.05). See Table 3 for details.

[0063] Table 3. Changes in indicators before and after observation in patients with grade I and II myelosuppression in the two groups ( )

[0064]

[0065] *Comparison before and after observation in the mulberry and shiitake mushroom group, P<0.05;

[0066] #Comparison of improvement between the two groups after observation, P<0.05.

[0067] (4) Changes in indicators before and after observation in the two groups of patients with grade III and IV myelosuppression.

[0068] After 21 days, no significant improvement was observed in any of the indicators in patients with grade III and IV myelosuppression in the non-mulberry and mulberry group (P>0.05). In the mulberry and mulberry group, only the platelet count increased significantly (P<0.05), while the other indicators showed no significant improvement (P>0.05). After adjusting for relevant influencing factors, the improvement in platelet count in the mulberry and mulberry group was significantly better than that in the non-mulberry and mulberry group (P<0.05). See Table 4 for details.

[0069] Table 4. Changes in indicators before and after observation in patients with grade III and IV myelosuppression in the two groups ( )

[0070]

[0071] *Comparison before and after observation in the mulberry and shiitake mushroom group, P<0.05;

[0072] #Comparison of improvement between the two groups after observation, P<0.05.

[0073] (5) Comparison of bone marrow suppression before and after observation in the two groups

[0074] The hemoglobin inhibition rate decreased by 4.99% in the mulberry and shiitake mushroom group, while it increased by 2.23% in the non-mulberry and shiitake mushroom group (P>0.05). The inhibition rates of white blood cells, neutrophils, and platelets improved by 23.37%, 13.34%, and 21.66%, respectively, in the mulberry and shiitake mushroom group (P<0.05). Except for hemoglobin, the improvements in other indicators were better in the mulberry and shiitake mushroom group than in the non-mulberry and shiitake mushroom group (P<0.05). See Table 5 for details.

[0075] Table 5 Comparison of bone marrow suppression rates before and after observation in the two groups (n) %

[0076]

[0077] * Comparison of bone marrow suppression rate before and after observation in the mulberry and antler group, P<0.05;

[0078] # Comparison of improvement in bone marrow suppression between the two groups, P<0.05.

[0079] (6) Safety evaluation

[0080] No adverse reactions related to the use of the mulberry and velvet compound extract were observed during the observation period, including liver and kidney function, stomach...

[0081] Intestinal reactions and general condition (vital signs, diet, bowel movements, sleep, skin and mucous membranes, mental state, etc.).

[0082] This prospective cohort clinical study, with an observation period of 21 days, showed that the compound extract of mulberry and antler velvet had a mitigating effect on the side effects of myelosuppression in cancer patients, especially in the early stages. No related adverse reactions were found, consistent with previous research results, providing a safe and effective treatment option for myelosuppression.

[0083] The undescribed parts of this invention are the same as or implemented using existing technology. The applicant declares that this invention is illustrated through the above specific embodiments, but the invention is not limited to the above detailed methods, i.e., it does not mean that the invention must rely on the above detailed methods to be implemented. Those skilled in the art should understand that any improvements to this invention, equivalent substitutions of raw materials for the product of this invention, additions of auxiliary components, and selection of specific methods all fall within the protection and disclosure scope of this invention.

Claims

1. A pharmafood compound extract for improving myelosuppression after chemotherapy in a tumor patient, characterized in that, The compound extract was obtained from a combination of raw materials containing at least the following parts by weight: 0.9–10 parts by weight of matsutake mushroom, 0.9–10 parts by weight of mulberry, and 0.5–10 parts by weight of polygonatum.

2. The pharmafood compound extract for improving myelosuppression after chemotherapy in a tumor patient according to claim 1, characterized in that, The active pharmaceutical ingredient combination also includes the following active pharmaceutical ingredients in parts by weight: 0.7–10 parts longan, 0.5–10 parts dried tangerine peel, 0.5–10 parts roasted hawthorn, 0.5–10 parts amomum villosum, 1.1–10 parts cordyceps rice flour, and 2.5–15 parts rice peptide.

3. The medicinal and edible compound extract for improving bone marrow suppression after chemotherapy in cancer patients according to claim 2, characterized in that, The active pharmaceutical ingredient combination consists of the following active pharmaceutical ingredients in parts by weight: 5-5.5 parts matsutake mushroom, 5-5.5 parts mulberry, 5-5.5 parts polygonatum, 5-5.5 parts longan, 5-5.5 parts dried tangerine peel, 5-5.5 parts roasted hawthorn, 5-5.5 parts amomum villosum, 5-6 parts cordyceps rice flour, and 6-8 parts rice peptide.

4. The medicinal and edible compound extract for improving bone marrow suppression after chemotherapy in cancer patients according to any one of claims 1 to 3, characterized in that, The compound extract is a liquid preparation.

5. The method for preparing the medicinal and edible homologous compound extract for improving bone marrow suppression after chemotherapy in cancer patients as described in claim 4, characterized in that, The process includes the following steps: after mixing the above-mentioned raw materials by weight, soaking them in a container for a certain period of time, decocting them under normal pressure, filtering out the liquid, and obtaining an aqueous extract for drinking.

6. The method for preparing the medicinal and edible homologous compound extract for improving bone marrow suppression after chemotherapy in cancer patients as described in claim 4, characterized in that, Add 0.9–10g of mulberry, 0.9–10g of matsutake mushroom, 0.7–10g of longan, 0.5–10g of dried tangerine peel, 0.5–10g of charred hawthorn, 0.5–10g of polygonatum, 0.5–10g of amomum villosum, 1.1–10g of cordyceps rice powder, and 2.5–15g of rice peptide to 100ml of water and steep or decoct to obtain a single-serving extract.

7. The use of the medicinal and edible compound extract according to any one of claims 1 to 3 in the preparation of drugs or health foods that improve bone marrow suppression in cancer patients undergoing radiotherapy and chemotherapy.

Images